<DOC>
	<DOCNO>NCT01437943</DOCNO>
	<brief_summary>The purpose study evaluate effect short-term aliskiren treatment kidney metabolism patient high risk develop kidney dysfunction ( i.e . kidney transplant patient ) . The study aim evaluate effect kidney metabolism [ use proton MR Spectroscopy ( 1H-MRS ) ] detect follow 6 month treatment aliskiren regardless anti-hypertensive role . 1H-MRS record large number chemical specie ( 40 ) kidney , monitor change accord pathologic state health transplant kidney .</brief_summary>
	<brief_title>Effect Short Term Aliskiren Treatment Kidney Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Stable patient end stage renal disease receive cadaveric kidney transplantation enrol . Patients must least 6 month followup include study . Patients must stable creatinine level last 6 month ( change &gt; 0.5 mg/dl ) . Patients systolic blood pressure 120 Serum potassium &gt; 5.0 mmol/L ( visit directly precede Randomization ) ; History cardiovascular event ( stroke , TIA , MI , unstable angina , CABG , percutaneous coronary intervention , hospitalization due HF ) 3 month prior Visit 1 . If patient experience event Visit 1 randomization Visit 3 , he/she withdrawn screen phase . If suitable , patient rescreened later stage ; Hypertension ( enrollment ) : patient msSBP ≥ 170 mmHg msDBP ≥ 110 mmHg ; Congestive heart failure NYHA class III IV ; Concomitant treatment two ( 2 ) reninangiotensinaldosterone system block agent , e.g . ACEI , ARB aldosteroneantagonist ; Unstable serum creatinine , patient creatinine &gt; 2.5 mg/dl enrol ; Second ( II ) third ( III ) degree heart block without pacemaker ; Concurrent potentially life threaten arrhythmia uncontrolled arrhythmia ; Clinically significant valvular heart disease ; Known renal artery stenosis ; Any surgical medical condition might significantly alter absorption , distribution , metabolism , excretion study drug include , limited , follow : ( ) History major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection ( patient previous bariatric surgery &gt; 6 month prior Visit 1 allow participate ) ; ( ii ) Any history pancreatic injury , pancreatitis evidence impair pancreatic function/injury indicate abnormal lipase amylase ; ( iii ) Evidence hepatic disease determine one following : SGPT value exceed 3 x Upper Limit Normal ( ULN ) Visit 1 , history hepatic encephalopathy , history cirrhosis , esophageal varix , history portocaval shunt . History malignancy basal cell skin cancer within past five year . Any concurrent life threaten condition life expectancy le 2 year . History evidence drug alcohol abuse within last 12 month . Any surgical medical condition , opinion investigator , may place patient high risk his/her participation study , likely prevent patient comply requirement study complete study . History hypersensitivity study drug medication belong therapeutic class study drug well know suspect contraindication study drug . History noncompliance medical regimen unwillingness comply study protocol . Use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever longer Any condition opinion investigator would jeopardize evaluation efficacy safety . Persons directly involved execution protocol . Pregnant nursing ( lactate ) woman Women ChildBearing Potential ( WOCBP ) unless postmenopausal least one year , surgically sterile use effective method contraception define local Health Authorities . Treatment Cyclosporine . Exclusion criterion include MR contraindication : electrical implant cardiac pacemaker perfusion pump ferromagnetic implant aneurysm clip , surgical clip , prosthesis , artificial heart , valve steel part , metal fragment , shrapnel , tattoo near eye , steel implant ferromagnetic object jewelry metal clip clothing pregnant volunteer preexist medical condition include likelihood develop seizure claustrophobic reaction great normal potential cardiac arrest subject less 18 year age .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Transplant</keyword>
	<keyword>Failure</keyword>
	<keyword>Kidney</keyword>
</DOC>